Novo Nordisk (NVOlowwageringcasinobonus.US) will issue bonds for the first time in more than two years as a blockbuster druglowwageringcasinobonusProvide funding for the production increase plan. Strong demand for Novo Nordisk's diabetes drug Ozempic and weight-loss drug Wegovy has pushed Novo Nordisk to become the most valuable company in Europe. A Novo Nordisk spokesman said the proceeds will be used to help the Danish pharmaceutical giant acquire the Catalent plant for $11 billion.

On Tuesday, banks will sell euro-denominated bonds with four maturities on behalf of Novo Nordisk through its Dutch financial subsidiary, with maturities ranging from two to 10 years, according to people familiar with the matter.

The popularity of Ozempic and Wegovy has increased due to their weight-loss benefits, prompting Novo Nordisk to increase its popularity earlier this month.lowwageringcasinobonusThe forecast for 2024 said sales could surge by 27%. The company is investing heavily to expand its production capacity and earlier this year announced plans to acquire three factories originally owned by Catalent, a deal expected to be completed by the end of the year.